PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27071708-12	2016	In addition, hypermethylation has been observed for the same genes in PAs and PCs (e.g. SFRP1, CDKN2A and WT1).	Protactinium	70-73	cyclin dependent kinase inhibitor 2A	Homo sapiens	95-101	
34190396-3	2021	The results confirmed that hepatocyte senescence occurred in HFD-fed Golden hamsters and PA-treated LO2 cells as manifested by increased levels of senescence marker SA-beta-gal, p16 and p21, heterochromatin marker H3K9me3, DNA damage marker gamma-H2AX and decreased activity of telomerase.	Protactinium	89-91	cyclin dependent kinase inhibitor 2A	Homo sapiens	178-181	
21610151-5	2011	RESULTS: Our results indicate that PAs are senescent as evidenced by marked senescence-associated acidic beta-galactosidase activity, low KI-67 index, and induction of p16(INK4a) but not p53 in the majority of 52 PA samples (46 of 52; 88.5%).	Protactinium	35-38	cyclin dependent kinase inhibitor 2A	Homo sapiens	168-171	
21610151-5	2011	RESULTS: Our results indicate that PAs are senescent as evidenced by marked senescence-associated acidic beta-galactosidase activity, low KI-67 index, and induction of p16(INK4a) but not p53 in the majority of 52 PA samples (46 of 52; 88.5%).	Protactinium	35-38	cyclin dependent kinase inhibitor 2A	Homo sapiens	172-177	
21610151-10	2011	We show that it is triggered in PAs through p16(INK4a) pathway induction following aberrant MAPK activation.	Protactinium	32-35	cyclin dependent kinase inhibitor 2A	Homo sapiens	44-47	
21610151-10	2011	We show that it is triggered in PAs through p16(INK4a) pathway induction following aberrant MAPK activation.	Protactinium	32-35	cyclin dependent kinase inhibitor 2A	Homo sapiens	48-53	
15608367-2	2004	The purpose of the study was to compare the prevalence of p16 and K-ras mutation in PA and CP in order to evaluate their usefulness in differential diagnosis of those diseases.	Protactinium	84-86	cyclin dependent kinase inhibitor 2A	Homo sapiens	58-61	
15608367-6	2004	Prevalence of p16 mutations in patients with PA was 18 (78,3%) and with CP - 7 (33,3%) (p<0,01).	Protactinium	45-47	cyclin dependent kinase inhibitor 2A	Homo sapiens	14-17	
8923213-7	1996	Expression of mRNA for the tissue inhibitor of metalloproteinases (TIMP)-1, and of the smaller of two mRNA species for the PA inhibitor PAI-1, ceased by P14.	Protactinium	123-125	cyclin dependent kinase inhibitor 2A	Homo sapiens	153-156	
20044755-6	2010	Neither 1p, 9p, and 10q nor 19q showed significant association with outcome in PAs, although p16 deletion was more common in PAs of the midbrain, brainstem, and spinal cord.	Protactinium	125-128	cyclin dependent kinase inhibitor 2A	Homo sapiens	93-96